1,450 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Mark Sheptoff Financial Planning LLC

Mark Sheptoff Financial Planning LLC acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,450 shares of the specialty pharmaceutical company’s stock, valued at approximately $52,000.

A number of other hedge funds have also recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $6,847,000. Great Lakes Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $6,131,000. American Century Companies Inc. grew its stake in shares of Supernus Pharmaceuticals by 9.2% in the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after buying an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after buying an additional 91,354 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after buying an additional 74,438 shares during the last quarter.

Insider Buying and Selling

In related news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Trading Up 1.1 %

Supernus Pharmaceuticals stock opened at $33.05 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a fifty day simple moving average of $35.49 and a two-hundred day simple moving average of $35.05. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 30.89 and a beta of 0.83.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.